Myeloma and Plasma Cell Dyscrasias
In association with Blood Cancer Discovery
November 3-5, 2022
Westin Copley Place
The American Association for Cancer Research (AACR) has made the difficult decision to postpone the Myeloma and Plasma Cell Dyscrasias meeting originally scheduled for November 3-5, 2022, in Boston, Massachusetts. Please note that this postponement applies to this meeting and does not apply to other planned AACR events.
We recognize that the new data, exchange of information, and opportunities for collaboration offered by this meeting are highly valued by the cancer research community, and we are working to reschedule the meeting in early 2023. Information on the rescheduled program will be sent by email and posted on www.aacr.org once it is available.
- If you submitted an abstract, please be advised that the abstracts that were submitted to the meeting will not be published as originally scheduled. We encourage authors to submit an updated abstract once submission opens for the new meeting dates. If you have any questions, please email [email protected].
- If you registered for the meeting, the AACR will issue a refund in the manner in which it was received. If you have any questions, please contact [email protected].
- If you have a room reservation at the Westin Copley Place, your cancellation will be accepted at no charge four (4) days in advance of your scheduled check-in date; please contact the hotel at (617) 262-9600 to cancel your reservation as soon as possible.
- If you booked a flight to Boston, many airlines have adjusted their rebooking and cancellation policies since the COVID-19 pandemic. Please contact your airline or booking agent directly to cancel your travel to Boston.
The AACR deeply appreciates your patience and understanding. Please look for emails in the coming weeks as we work to reschedule this program as soon as possible. If you have any questions, please email [email protected].
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Massachusetts
Irene M. Ghobrial, Dana-Farber Cancer Institute, Boston, Massachusetts